Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.58 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | SCN1A | P35498 | 2/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957689 | 0.84 | CARM1 (0.59) | HRH1CARM1PRMT1NPY1RNPY2R | |
| SCHEMBL22957842 | 0.83 | CARM1 (0.61) | HRH1CARM1PRMT1NPY1RNPY2R | |
| SCHEMBL14624279 | 0.83 | HRH1 (0.62) | HRH1CARM1PRMT1SMN1; SMN2SCN1A | |
| SCHEMBL16814965 | 0.82 | KAT2B (0.57) | HRH1CARM1PRMT1PRMT6HTR2A | |
| SCHEMBL3289933 | 0.82 | HRH1 (0.57) | HRH1CARM1PRMT1SMN1; SMN2SCN1A | |
| SCHEMBL14578192 | 0.79 | HRH1 (0.68) | HRH1CARM1SMN1; SMN2SCN1ASCN2A | |
| SCHEMBL899883 | 0.77 | HRH1 (0.66) | HRH1SMN1; SMN2SCN1ASCN2ASCN3A | |
| SCHEMBL21486437 | 0.77 | HRH1 (0.53) | HRH1CARM1PRMT1SMN1; SMN2SCN1A | |
| SCHEMBL24018776 | 0.77 | MCHR1 (0.45) | HRH1CARM1PRMT1HTR2ASLC6A4 | |
| SCHEMBL22957814 | 0.77 | KAT2B (0.48) | HRH1CARM1PRMT1HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196453-A1 | Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents | Cellvir (FR) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | HRH1 2995/4885CARM1 3129/4885PRMT1 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.